U.S. markets open in 1 hour 3 minutes
  • S&P Futures

    3,661.50
    +7.25 (+0.20%)
     
  • Dow Futures

    29,305.00
    +20.00 (+0.07%)
     
  • Nasdaq Futures

    11,249.25
    +21.00 (+0.19%)
     
  • Russell 2000 Futures

    1,688.80
    +6.70 (+0.40%)
     
  • Crude Oil

    80.22
    -1.01 (-1.24%)
     
  • Gold

    1,671.80
    +3.20 (+0.19%)
     
  • Silver

    18.90
    +0.19 (+1.00%)
     
  • EUR/USD

    0.9777
    -0.0042 (-0.43%)
     
  • 10-Yr Bond

    3.7470
    0.0000 (0.00%)
     
  • Vix

    31.45
    +1.27 (+4.21%)
     
  • GBP/USD

    1.1066
    -0.0057 (-0.52%)
     
  • USD/JPY

    144.6590
    +0.2160 (+0.15%)
     
  • BTC-USD

    19,418.84
    +33.99 (+0.18%)
     
  • CMC Crypto 200

    443.92
    -2.06 (-0.46%)
     
  • FTSE 100

    6,889.27
    +7.68 (+0.11%)
     
  • Nikkei 225

    25,937.21
    -484.84 (-1.83%)
     

Ziopharm Rebrands As Alaunos Therapeutics

·1 min read

Ziopharm Ocology Inc (NASDAQ: ZIOP) has rebranded itself and has changed its name to Alaunos Therapeutics Inc.

  • The Company will trade on NASDAQ under the new ticker symbol "TCRT" to be effective tomorrow.

  • Along with the name change, the Company amended Phase 1/2 IND to add four additional T-cell receptors (TCRs) to its library, increasing the number of eligible patients for the clinical trial.

  • Related: Ziopharm Shares Are Trading Lower After Slashing Workforce By Over 50%.

  • Phase 1/2 TCR-T library trial targeting KRAS, TP53, and EGFR mutations across six solid tumor indications is open for enrollment at Texas' MD Anderson Cancer Center.

  • Dosing is expected to start in 1H of 2022.

  • Additionally, to streamline operations, the Company has closed its Boston office. Alaunos will be headquartered in Houston.

  • Price Action: ZIOP shares are up 1.02% at $0.88 during the market session on the last check Wednesday.

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.